Health & Environmental Research Online (HERO)


Print Feedback Export to File
7282064 
Journal Article 
Review 
SARS-CoV-2 and cardiovascular complications: From molecular mechanisms to pharmaceutical management 
Wu, L; O'Kane, AM; Peng, H; Bi, Y; Motriuk-Smith, D; Ren, J 
2020 
Yes 
Biochemical Pharmacology
ISSN: 0006-2952
EISSN: 1873-2968 
178 
114114 
English 
32579957 
WOS:000551658300052 
The coronavirus disease 2019 (COVID-19), elicited by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, is a pandemic public health emergency of global concern. Other than the profound severe pulmonary damage, SARS-CoV-2 infection also leads to a series of cardiovascular abnormalities, including myocardial injury, myocarditis and pericarditis, arrhythmia and cardiac arrest, cardiomyopathy, heart failure, cardiogenic shock, and coagulation abnormalities. Meanwhile, COVID-19 patients with preexisting cardiovascular diseases are often at a much higher risk of increased morbidity and mortality. Up-to-date, a number of mechanisms have been postulated for COVID-19-associated cardiovascular damage including SARS-CoV-2 receptor angiotensin-converting enzyme 2 (ACE2) activation, cytokine storm, hypoxemia, stress and cardiotoxicity of antiviral drugs. In this context, special attention should be given towards COVID-19 patients with concurrent cardiovascular diseases, and special cardiovascular attention is warranted for treatment of COVID-19.